RTP Mobile Logo
Submitted by web@researchtop... on Wed, 05/15/2019 - 14:49
LCURadOnc119

Interview with Andreas Rimner, MD

Track 1: Evaluation, staging and typical disease management approaches for patients with locally advanced non-small cell lung cancer (NSCLC)
Track 2: Selection and dose of postoperative radiation therapy (RT)
Track 3: Stereotactic body RT (SBRT) versus surgery for patients with early-stage NSCLC
Track 4: Case: A man in his mid-70s, a former smoker, with Stage IIIC adenocarcinoma of the lung receives durvalumab consolidation after chemoradiation therapy (CRT)
Track 5: Optimal design of the radiation treatment field; mitigation of RT-associated side effects
Track 6: Results of the Phase III RTOG-0617 trial evaluating carboplatin/paclitaxel in combination with standard- versus high-dose conformal RT, with or without cetuximab, for Stage III NSCLC
Track 7: Role of RT in enhancing tumor immunogenicity
Track 8: Avoiding safety concerns with the combination of CRT and immune checkpoint inhibitors
Track 9: Activity and tolerability of pembrolizumab after RT in patients with NSCLC on the Phase I KEYNOTE-001 trial
Track 10: PACIFIC trial: Efficacy and tolerability of durvalumab after CRT for patients with unresectable Stage III NSCLC
Track 11: Activity of durvalumab after CRT; diagnosis and management of pneumonitis associated with durvalumab/CRT
Track 12: Ongoing Phase II trial evaluating the activity and safety of nintedanib with prednisone for the treatment of radiation pneumonitis
Track 13: Incidence of pneumonitis with CRT alone and with the addition of durvalumab
Track 14: Survival outcomes and duration of consolidation therapy with durvalumab
Track 15: Ongoing evaluation of immune checkpoint inhibitors with concurrent RT with or without chemotherapy
Track 16: Activity of immune checkpoint inhibitors in the neoadjuvant setting
Track 17: Selection of the optimal dose and technique of RT for locally advanced NSCLC
Track 18: Case: A woman in her early 70s with unresectable Stage IIIB adenocarcinoma of the lung and a KRAS mutation receives CRT followed by durvalumab
Track 19: Clinical experience with the use of durvalumab after CRT
Track 20: Case: A woman in her mid-50s with Stage III adenocarcinoma of the lung and an EGFR mutation receives adjuvant osimertinib
Track 21: Increased RT precision with the merging of MRI and a linear accelerator

Interview with Corey J Langer, MD

Track 1: Case: A woman in her mid-60s, a never smoker, with locally advanced, unresectable adenocarcinoma of the lung and an EGFR exon 18 tumor mutation receives CRT followed by consolidation durvalumab
Track 2: Clinical significance and prognostic relevance of microsatellite instability testing in the management of lung cancer
Track 3: Risk of recurrence after concurrent CRT for patients with Stage III NSCLC
Track 4: Improvement in progression-free and overall survival with the addition of consolidation durvalumab after CRT for patients with Stage III NSCLC on the PACIFIC trial
Track 5: Role of immune checkpoint inhibition in the treatment of locally advanced NSCLC with an EGFR tumor mutation
Track 6: Perspective on the use of EGFR tyrosine kinase inhibitors in the adjuvant or neoadjuvant setting for patients with locally advanced NSCLC and EGFR tumor mutations
Track 7: Initial diagnostic workup and disease management for patients with locally advanced NSCLC
Track 8: RTOG-1308: An ongoing Phase III trial of photon versus proton CRT for patients with inoperable Stage II to Stage IIIB NSCLC
Track 9: Role of proton beam RT in the treatment of locally advanced NSCLC
Track 10: Rationale for the combination of RT and immune checkpoint inhibitors
Track 11: Risk of pneumonitis with CRT
Track 12: Design and results of the Phase III PACIFIC trial of durvalumab after CRT for unresectable Stage III NSCLC
Track 13: Monitoring and management of the toxicities associated with immune checkpoint inhibitors
Track 14: Use of durvalumab for patients with preexisting autoimmune disease and for transplant recipients
Track 15: Results from the Phase II Hoosier Cancer Research Network LUN14-179 trial of consolidation pembrolizumab after CRT for unresectable Stage III NSCLC
Track 16: Ongoing investigation of anti-PD-1/PD-L1 immune checkpoint inhibitors for locally advanced disease
Track 17: Case: A man in his mid-80s, a former heavy smoker with multiple comorbidities, is diagnosed with locally advanced squamous cell carcinoma of the lung with a high PD-L1 TPS (tumor proportion score)
Track 18: Use of liquid biopsies to detect targetable tumor mutations in patients with lung cancer
Track 19: Case: A man in his mid-50s, a former smoker, is diagnosed with Stage IIIA mixed adenosquamous carcinoma of the lung with TTF-1 and p40 tumor mutations
Track 20: Perspective on the use of anti-PD-1/PD-L1 antibodies as neoadjuvant therapy for patients with NSCLC
Track 21: Case: A man in his early 70s, a current smoker, with adenosquamous carcinoma of the lung and a KRAS mutation receives SBRT
Track 22: Optimal approach to RT for patients with locally advanced NSCLC
 
FACULTY
 
Andreas Rimner, MD
Associate Attending
Department of Radiation Oncology
Memorial Sloan Kettering Cancer Center
New York, New York
 
Corey J Langer, MD
Director of Thoracic Oncology
Abramson Cancer Center
Professor of Medicine
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida